drugset / Trial / NCT05118958
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a 3 part, phase 1 crossover study in healthy subjects to evaluate the pharmacokinetic profile of KVD824 following single and multiple doses of novel KVD824 modified-release formulations compared with a reference KVD824 immediate release formulation.
Timeline
- Start
- 2020-05-19
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FENIRALSTAT | Small molecule | 300 mg | Oral |
| Subject | FENIRALSTAT | Small molecule | 600 mg | Oral |
| Subject | FENIRALSTAT | Small molecule | 900 mg | Oral |